Authors

Latest:

Dr Esteva on the Impact of the MAINTAIN Trial in HR+/HER2– Breast Cancer

Francisco J. Esteva, MD, PhD, discusses the impact of the phase 2 MAINTAIN study of treatment with ribociclib following progression on CDK4/6 inhibition in patients with hormone receptor-positive, HER2-negative breast cancer.

Francisco Esteva, MD, PhD, Langone Medical Center

Francisco J. Esteva, MD, PhD

Latest:

Dr Esteva on the monarchE and NATALEE Trials in HR+/HER2– Breast Cancer

Francisco J. Esteva, MD, PhD, discusses the phase 3 monarchE and NATALEE trials in patients with hormone receptor–positive/HER2-negative breast cancer.

Francisco Marty, MD

Latest:

Dr. Marty on Letermovir for CMV Prevention After Stem Cell Transplant

Francisco Marty, MD, Dana-Farber Cancer Institute, discusses the initial results of the Phase III trial evaluating letermovir for CMV after bone marrow transplant.

Franco M. Muggia, MD

Latest:

Integrating PARP Inhibitors Into the Treatment of Women

After years in development, several PARP inhibitors have achieved indications in ovarian cancer treatment, while others continue in development and expanding indications.

Franco M. Muggia, MD, PhD

Latest:

Dr. Muggia on Targeted Therapies for Ovarian Cancer

Franco M. Muggia, MD, PhD, professor, Department of Medicine, NYU Langone Medical Center, discusses targeted therapies for patients with ovarian cancer.

Franco Muggia, MD

Latest:

Dr. Muggia on Current Status of Intraperitoneal Therapy for Gynecologic Cancers

Franco Muggia, MD, professor of Medicine, NYU Langone Medical Center, discusses the current status of intraperitoneal therapy for patients with gynecologic malignancies.

Francois-Clement Bidard, MD, PhD

Latest:

Dr. Bidard on the FDA Approval of Elacestrant in ER+/HER2– Metastatic Breast Cancer

François-Clément Bidard, MD PhD, discusses the significance of the FDA approval of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer and key efficacy and safety data from the phase 3 EMERALD trial.

Francoise G. Pradel, PhD

Latest:

Racial/Ethnic and Age Disparities in Chemotherapy Selection for Colorectal Cancer

Studies have evaluated racial/ethnic and age disparities in whether patients receive chemotherapy for nonmetastatic colo-rectal cancer

Francoise Horand

Latest:

Erythrocytes Used as Tumor Antigen Delivery System

FranÃ§oise Horand, director, R&D Operations, Erytech Pharma, discusses a study investigating the use of erythrocytes as a tumor antigen delivery system to target antigen-presenting cells and induce efficient immune response against tumors.

Frank A. Sinicrope, MD

Latest:

Dr Sinicrope on the Clinical Implications of the ATOMIC Trial for Stage III dMMR CRC

Frank A. Sinicrope, MD, discuses the implications of data with atezolizumab plus adjuvant mFOLFOX6 for the management of stage III, dMMR colon cancer.

Frank A. Vicini, MD

Latest:

Dr. Vicini on the Potential Utility of the DCISionRT Test in HER2+ DCIS of the Breast

Frank A. Vicini, MD, discusses the potential utility of using the DCISionRT test to determine treatment benefit in the phase 3 NRG-NSABP-B43 trial in HER2-positive ductal carcinoma in situ of the breast.

Frank A. Vicini, MD, FACR

Frank delaRama, RN, MS, AOCNS

Latest:

Frank delaRama on Patient Education in Prostate Cancer

Frank delaRama, RN, MS, AOCNS®, from the Palo Alto Medical Foundation, explains the role of oncology nurse navigators in providing relevant information to men with prostate cancer.

Frank E. Mott, MD

Latest:

Dr. Mott on Sequencing of Treatments with NSCLC

Frank E. Mott, MD, associate professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the sequencing of treatments for patients with non-small cell lung cancer (NSCLC).

Frank E. Mott, MD, FACP

Latest:

Dr. Mott Discusses Targeted Therapy for ALK+ NSCLC

Frank E. Mott, MD, FACP, department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses taregeted therapy for ALK-positive non-small cell lung cancer (NSCLC).

Frank Ferrara

Latest:

Argumentum Ad Populum: Medical Wikis 101

What exactly is a medical wiki, and for that matter, a wiki in general? Are these resources useful to you and your patients?

Frank Vicini, MD

Latest:

Hypofractionated and Stereotactic Body Radiotherapy in Prostate Cancer

Despite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.

Frankie Ann Holmes, MD

Latest:

Dr. Holmes on Neoadjuvant Endocrine Therapy in Breast Cancer

Frankie Ann Holmes, MD, a physician at Texas Oncology, discusses neoadjuvant endocrine therapy for patients with breast cancer.

Fred C. Kass, MD

Latest:

Dr. Kass on Optimal Treatment Sequencing in HER2-Positive Breast Cancer

Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, discusses challenges associated with optimal treatment sequencing for patients with HER2-positive breast cancer.